TNFRSF17 and Miyoshi myopathy: ISB 2001 showed similar potency to anti-BCMA TCEs on CD38 knockout (KO) NCI-H929 cells but also induced killing of MM cells when BCMA was absent, unlike other TCEs tested (Fig. 3g,h).